retatrutide trial duration Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Eli Lilly and Company's retatrutide
Description
Weight regain after stopping GLP-1s is real and still a concern, particularly for people who stop without any follow-up treatment plan
That being said only 4.1 % of patients stopped the 4mg dose which is less than the placebo arm
A., Pozzi, E., Deebel, N
What symptoms
